Definium Therapeutics CFO Brandi Roberts Sells Shares
CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics on June 25, 2026.
Key Points
- Brandi Roberts, CFO of Definium Therapeutics, sold 3,013 shares at an average price of $45.03, totaling $135,675 on June 25, 2026.
- Definium Therapeutics, with a market cap of $5.97 billion, has a 52-week range between $6.40 and $47.01 and a beta of 2.378.
- Analysts maintain a 'strong buy' consensus with a target mean price of $56.00, supported by recent insider sales.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Brandi Roberts, the Chief Financial Officer of Definium Therapeutics, Inc. (NasdaqGS: DFTX), sold 3,013 shares of the company. The shares were sold at an average price of $45.03, resulting in a total transaction value of $135,675. This sale was conducted under a pre-arranged trading plan.
Insider Buying and Selling at Definium Therapeutics, Inc.
Alongside Brandi Roberts, several other executives at Definium Therapeutics also sold shares on June 25, 2026. CEO Robert Barrow sold 29,208 shares, Chief Medical Officer Daniel Karlin sold 10,035 shares, Chief Legal Officer Mark Sullivan sold 13,008 shares, and Chief Commercial Officer Matthew Wiley sold 2,867 shares. All these transactions were executed at an average price of $45.03 per share and were part of planned sales.
Definium Therapeutics, Inc. Stock Up 9.7%
Shares of NasdaqGS: DFTX traded near $44.95 on Saturday. Definium Therapeutics has a market capitalization of approximately $5.97 billion. The stock has experienced significant volatility with a 52-week low of $6.40 and a high of $47.01. The company has a 50-day moving average of $24.52 and a 200-day moving average of $17.07. Despite its growth potential, the company is not yet profitable, reflected by its negative forward P/E ratio of -28.83.
$DFTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Recently, several analysts have maintained their 'buy' ratings for Definium Therapeutics. On June 24, 2026, Jones Trading reaffirmed its buy rating with a price target of $74.0. Baird and Needham also maintained their buy ratings on June 23, with targets of $57.0 and $50.0, respectively. The consensus among 15 analysts is a strong buy, with an average target price of $56.00.
About Definium Therapeutics
Definium Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for brain health disorders. Based in New York, the company is advancing its lead product candidates, DT120 and DT402, through clinical trials to address conditions like generalized anxiety disorder and autism spectrum disorder. Led by CEO Robert Barrow, the company employs 105 people and operates in the biotechnology industry.
Bottom Line
Brandi Roberts' recent sale of shares in Definium Therapeutics is part of a broader trend of insider transactions at the company. Investors often watch these moves closely, although they do not necessarily indicate the company's future performance. As Definium Therapeutics continues to develop its innovative treatments, the market will be watching for its next earnings report on July 30, 2026.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.